FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> ustekinumab | Centocor | Johnson & Johnson

FDA committee backs Centocor psoriasis drug

Tools

J&J's Centocor won a key vote by an FDA expert committee backing the approval of ustekinumab for moderate to severe psoriasis. But the experts also want to make sure that the developer continues studies exploring possible links between the drug and a heightened risk of cancer and infections. The drug works by targeting the patient's immune system.

"This drug has the potential to be so helpful for patients, and I think it raises an ethical question if we keep it from them," said panel member Lynn A. Drake.

- check out this release
- read the story from Dow Jones

Related Articles:
J&J psoriasis drug may carry cancer risk
Strong Phase III data for J&J's psoriasis drug
Insurers shun new biologics for psoriasis
Biotech drugs offer first real help for severe psoriasis

More stories about ustekinumab   Centocor   Johnson & Johnson  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.